May 10th 2017 Transenterix Inc announced finanical results and business update for Q1 2017. The financial results included
-Sale of 1 Senhance robot in Germany
-$17M new credit line that allowed the company to refinance all existing debt.
The company has about $48M in cash which is enough to fund operations through Q2 2018 including launch of the Senhance sales in the U.S. if the robot is approved by the FDA
The company continued building sales infrastrucutre in Europe. In total the Company placed 7 robots for demo and training purposes covering the major markets - the U.K., Germany, France, and Italy.
May 10th 2017 Array Biopharma Inc announced financial results and business update for Q1 2017. Regarding ongoing business events the following two attracted attention the most
-The company announced final results of the Columbus Phase 3 study in BRAF melanoma. The first part of the study was actually the decisive and last September Array said the study met its primary endpoint which already made it sufficient for an NDA to be filed to the US FDA. The second part of the study that ended recently was assessing whether the combination of 2 drugs made the treatment work or just one of the drugs. The second part results proved that the combination of the two drugs is essential and showed again efficacy and good tolerability of the treatment.
Array announced that given the strength of the data the NDA is going to be filed June-July this year.
-The second news (maybe more for the long term) was that Array had entered into collaboration with Merck and the two companies initiated a study evaluating efficacy of combination of Array drug binimetinib with Keytruda (Merck flagship drug for melanoma treatment)